
|Articles|September 1, 2003
Steroid is safe for treating conjunctivitis
Loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb Pharmaceuticals and Pharmos Corp.), the so-called "safe steroid" approved for treatment of seasonal allergic conjunctivitis, appears to be living up to its billing, according to several ophthalmologists who prescribe the drug for a range of ophthalmic allergies.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
New optoretinography technique allows direct measurement of rod function in vivo
2
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
3
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
4
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis
5












































